HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
Should sacituzumab plus pembrolizumab be used first‑line in TNBC?
Dr Huppert expresses enthusiasm for moving SG into first line, discusses KEYNOTE‑522 prior IO exposure and open questions.
Play episode from 16:18
Transcript
